CJC-1295

ID: cjc1295

Aliases: CJC-1295 with DAC, long-acting GHRH analog, CJC-1295 (WITH DAC)

Type: compound

Route/form: subcutaneous injection

Status: investigational_or_research

Evidence level: early human

Best data tier: early human + human physiology

Support scope: human, non-human/mechanistic

Source types: early_human, human_physiology, preclinical

Linked sources: 4

Broad outcomes: Fat loss / metabolic health, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GHRH receptor agonist
• GH/IGF-1 axis

Optimization domains

• growth hormone
• body composition

Research basis

• Human healthy-adult studies show long-acting CJC-1295 can raise GH and IGF-1 for days, and a companion physiology paper reports that pulsatile GH secretion can persist during continuous stimulation.
• The route/form distinction matters: CJC-1295 with DAC is a long-acting albumin-binding GHRH analog, while no-DAC products are better represented by the modified GRF(1-29) entry.
• The performance rationale is endocrine biomarker modulation, not direct proof of hypertrophy, recovery, or fat-loss outcomes.

Limits, risks, and missing evidence

• Healthy-volunteer GH/IGF-1 changes are not the same as proven body-composition or recovery benefit.
• Chronic GH/IGF-1 elevation can plausibly worsen edema, glucose tolerance, carpal-tunnel symptoms, sleep apnea, and growth-signal risk in susceptible people.
• Informal product naming often collapses DAC and no-DAC versions even though exposure pattern is the core pharmacology.

Risk flags

• investigational
• endocrine axis
• gh igf1 axis
• glucose edema risk
• route form ambiguity
• outcome extrapolation

Linked papers, labels, and reviews

1. Prolonged stimulation of GH and IGF-I secretion by CJC-1295
   early_human / pubmed_cjc1295_2006
   Healthy adult pharmacokinetic/pharmacodynamic study.
2. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects
   human_physiology / pubmed_cjc1295_proteomic_2009
   Healthy young adult men; direct human biomarker study after CJC-1295 exposure, useful for GH/IGF-1-axis mechanism rather than outcome claims.
3. Human growth hormone-releasing factor 1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats
   preclinical / pubmed_cjc1295_albumin_bioconjugate_2005
   Preclinical medicinal-biology source identifying CJC-1295 as a long-lasting GHRH analog; route and human benefit cannot be inferred from this alone.
4. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
   human_physiology / pubmed_cjc1295_pulsatile_2006
   Healthy-adult CJC-1295 physiology paper showing GH pulsatility can persist despite long-acting GHRH analog exposure.